MX2021000778A - Metodos de tratamiento y prevencion de la enfermedad de alzheimer. - Google Patents
Metodos de tratamiento y prevencion de la enfermedad de alzheimer.Info
- Publication number
- MX2021000778A MX2021000778A MX2021000778A MX2021000778A MX2021000778A MX 2021000778 A MX2021000778 A MX 2021000778A MX 2021000778 A MX2021000778 A MX 2021000778A MX 2021000778 A MX2021000778 A MX 2021000778A MX 2021000778 A MX2021000778 A MX 2021000778A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- disease
- alzheimer
- subject
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702659P | 2018-07-24 | 2018-07-24 | |
| US201862749614P | 2018-10-23 | 2018-10-23 | |
| US201962824162P | 2019-03-26 | 2019-03-26 | |
| US201962846902P | 2019-05-13 | 2019-05-13 | |
| US201962874684P | 2019-07-16 | 2019-07-16 | |
| PCT/US2019/043067 WO2020023530A2 (en) | 2018-07-24 | 2019-07-23 | Methods of treatment and prevention of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000778A true MX2021000778A (es) | 2021-03-31 |
Family
ID=67551415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000778A MX2021000778A (es) | 2018-07-24 | 2019-07-23 | Metodos de tratamiento y prevencion de la enfermedad de alzheimer. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210324056A1 (enExample) |
| EP (1) | EP3826674A2 (enExample) |
| JP (2) | JP7541505B2 (enExample) |
| KR (1) | KR20210039402A (enExample) |
| CN (2) | CN112805031A (enExample) |
| AU (1) | AU2019309938A1 (enExample) |
| BR (1) | BR112021001272A2 (enExample) |
| CA (1) | CA3107370A1 (enExample) |
| IL (3) | IL280315B2 (enExample) |
| MX (1) | MX2021000778A (enExample) |
| PH (1) | PH12021500006A1 (enExample) |
| TW (1) | TW202019471A (enExample) |
| WO (1) | WO2020023530A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| EP4121007B1 (en) * | 2020-03-20 | 2025-07-02 | Eisai R&D Management Co., Ltd. | High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| WO2022020680A1 (en) | 2020-07-23 | 2022-01-27 | Othair Prothena Limited | Anti-abeta antibodies |
| WO2022035758A1 (en) * | 2020-08-12 | 2022-02-17 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| TW202300517A (zh) * | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| EP4448005A1 (en) * | 2021-12-17 | 2024-10-23 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| WO2023111618A1 (en) * | 2021-12-17 | 2023-06-22 | Eisai R&D Management Co., Ltd. | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody |
| JP2025506389A (ja) * | 2022-02-02 | 2025-03-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ｐ－タウ１８１レベルを使用した治療方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| RU2429244C2 (ru) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Улучшенные селективные в отношении протофибрилл антитела и их применение |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| AU2016208353B2 (en) * | 2007-10-17 | 2017-07-20 | Janssen Alzheimer Immunotherapy | Immunotherapy regimes dependent on ApoE status |
| JP4520533B2 (ja) | 2008-01-18 | 2010-08-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合アミノジヒドロチアジン誘導体 |
| EP2448968B1 (en) | 2009-06-29 | 2021-01-27 | BioArctic AB | ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS |
| US20130084245A1 (en) * | 2010-02-25 | 2013-04-04 | Wyeth Llc | Pet monitoring of a-beta-directed immunotherapy |
| RU2555526C2 (ru) | 2010-02-26 | 2015-07-10 | Байоарктик Ньюросайенс Аб | Антитела, связывающиеся с протофибриллами, и их применение в методах терапии и диагностики болезни паркинсона, деменции, ассоциированной с образованием диффузных телец леви, и других альфа-синуклеинопатий |
| CN103502231A (zh) | 2011-01-21 | 2014-01-08 | 卫材R&D管理有限公司 | 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物 |
| RS61717B1 (sr) | 2014-07-10 | 2021-05-31 | Bioarctic Ab | Poboljšana antitela koja vezuju a-beta protofibril |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| EP3405489A1 (en) * | 2016-01-20 | 2018-11-28 | Genentech, Inc. | High dose treatments for alzheimer's disease |
| ES2939373T3 (es) * | 2016-05-13 | 2023-04-21 | Pasteur Institut | Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer |
| TWI735600B (zh) * | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| JP7116725B2 (ja) * | 2016-10-27 | 2022-08-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物 |
-
2019
- 2019-07-23 CN CN201980062781.8A patent/CN112805031A/zh active Pending
- 2019-07-23 CA CA3107370A patent/CA3107370A1/en active Pending
- 2019-07-23 US US17/250,448 patent/US20210324056A1/en active Pending
- 2019-07-23 WO PCT/US2019/043067 patent/WO2020023530A2/en not_active Ceased
- 2019-07-23 AU AU2019309938A patent/AU2019309938A1/en active Pending
- 2019-07-23 KR KR1020217005322A patent/KR20210039402A/ko not_active Ceased
- 2019-07-23 BR BR112021001272-9A patent/BR112021001272A2/pt unknown
- 2019-07-23 JP JP2021503770A patent/JP7541505B2/ja active Active
- 2019-07-23 CN CN202411217698.2A patent/CN118924896A/zh active Pending
- 2019-07-23 EP EP19750196.8A patent/EP3826674A2/en active Pending
- 2019-07-23 MX MX2021000778A patent/MX2021000778A/es unknown
- 2019-07-23 IL IL280315A patent/IL280315B2/en unknown
- 2019-07-24 TW TW108126224A patent/TW202019471A/zh unknown
-
2021
- 2021-01-21 PH PH12021500006A patent/PH12021500006A1/en unknown
-
2024
- 2024-01-14 IL IL310132A patent/IL310132B1/en unknown
- 2024-05-10 JP JP2024077300A patent/JP2024112859A/ja active Pending
-
2025
- 2025-09-25 IL IL323583A patent/IL323583A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210324056A1 (en) | 2021-10-21 |
| KR20210039402A (ko) | 2021-04-09 |
| IL323583A (en) | 2025-11-01 |
| CA3107370A1 (en) | 2020-01-30 |
| CN112805031A (zh) | 2021-05-14 |
| WO2020023530A3 (en) | 2020-03-12 |
| EP3826674A2 (en) | 2021-06-02 |
| IL280315B2 (en) | 2024-06-01 |
| JP2024112859A (ja) | 2024-08-21 |
| IL310132A (en) | 2024-03-01 |
| JP2021532126A (ja) | 2021-11-25 |
| IL280315B1 (en) | 2024-02-01 |
| WO2020023530A2 (en) | 2020-01-30 |
| PH12021500006A1 (en) | 2021-09-13 |
| CN118924896A (zh) | 2024-11-12 |
| JP7541505B2 (ja) | 2024-08-28 |
| AU2019309938A1 (en) | 2021-03-11 |
| TW202019471A (zh) | 2020-06-01 |
| IL280315A (en) | 2021-03-25 |
| BR112021001272A2 (pt) | 2021-04-27 |
| IL310132B1 (en) | 2025-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000778A (es) | Metodos de tratamiento y prevencion de la enfermedad de alzheimer. | |
| AR132544A2 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| CO2019011349A2 (es) | Anticuerpos anti-péptido beta amiloide n3pglu y sus usos | |
| MX2022007276A (es) | Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas. | |
| CO2020008287A2 (es) | Derivados de 1, 3, 4, 5-tetrahidro-2h-pirido[4,3-b]indol para el tratamiento, alivio o prevención de desórdenes asociados con los agregados de tau como la enfermedad de alzheimer | |
| CO2020014563A2 (es) | Uso de clorhidrato de pilocarpina para el tratamiento de condiciones oculares | |
| EA201892690A1 (ru) | АНТИТЕЛА К БЕТА-АМИЛОИДНОМУ ПЕПТИДУ N3pGlu И ИХ ПРИМЕНЕНИЕ | |
| MX2015015228A (es) | Sobetirome en el tratamiento de enfermedades de mielinizacion. | |
| CO2023009089A2 (es) | Anticuerpos anti-n3pglu beta amiloide y usos de estos | |
| ECSP20066233A (es) | Compuestos y sus usos para aliviar síntomas asociados a la menopausia | |
| CL2019003789A1 (es) | Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1. | |
| CO2021000932A2 (es) | Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma | |
| CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
| MX2021009488A (es) | Uso de vibegron para tratar la vejiga hiperactiva. | |
| BR112021010174A2 (pt) | Métodos para diagnóstico e / ou tratamento de doença aguda ou crônica de fígado, rim ou pulmão | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| AR053928A1 (es) | Metodos reactivos para el tratamiento de trastornos inflamatorios | |
| NI201100148A (es) | Uso de deferiprona para el tratamiento y la prevención de trastornos oculares relacionados con hierro. | |
| MX2022007844A (es) | Tratamiento de una lesion cerebral traumatica moderada. | |
| MX394351B (es) | Combinación de antagonista de nk1 y método para tratar sinucleinopatías. | |
| MX2015016951A (es) | Metodo de tratamiento de trastornos neurodegenerativos. | |
| CO2019013940A2 (es) | Métodos para reducir o prevenir episodios cardiovasculares en pacientes con diabetes mellitus tipo ii | |
| CL2023000270A1 (es) | Compuesto para el tratamiento de la enfermedad de alzheimer | |
| BRPI0511305A (pt) | método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1 | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. |